LCL161

For research use only. Not for use in humans.

目录号:S7009

LCL161 Chemical Structure

CAS No. 1005342-46-0

LCL-161, 一种second mitochondrial activator of caspase (SMAC, 线粒体促凋亡蛋白)模拟物, 能有效地结合并抑制多种IAPs(i.e. XIAP, c-IAP)。

规格 价格 库存 购买数量  
RMB 1194.96 现货
RMB 3883.15 现货
RMB 8176.93 现货
有超大折扣
今日订购,明日送达 全国免运费 分装免费
全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的LCL161发表文献25篇:

产品安全说明书

IAP抑制剂选择性比较

生物活性

产品描述 LCL-161, 一种second mitochondrial activator of caspase (SMAC, 线粒体促凋亡蛋白)模拟物, 能有效地结合并抑制多种IAPs(i.e. XIAP, c-IAP)。
靶点
cIAP [1] XIAP [1]
体外研究

LCL161以高亲和力与凋亡抑制蛋白因子(IAPs)结合,并启动对cIAP1和cIAP2的破坏,其通过胱天蛋白酶的激活进一步诱导细胞凋亡。LCL161单独给药时适度抑制表达FLT3-ITD的细胞生长,IC50的范围为~0.5 μM (Ba/F3-FLT3-ITD 细胞)到~4 μM (MOLM13-luc+ 细胞)。观察到的LCL161抗D835Y突变体的效力相当高,测试抗Ba/F3-D835Y细胞时,IC50为~50 nM。LCL161 与PKC412结合治疗MOLM13-luc+细胞比其任何一个药剂单独使用具有更显著的细胞杀伤力,Calcusyn复合指数表明其具有协同作用。 PKC412和LCL161诱导MOLM13-luc+细胞的凋亡。PKC412 和 LCL161结合比其单独使用能够导致更高的细胞凋亡率。LCL161通过与PKC412阳性结合,抑制基质介导的表达FLT3的突变细胞的存活。LCL161抑制Ba/F3.p210细胞的生长,IC50为~100 nM。LCL161与ABL抑制剂,伊马替尼结合,能够协同抗BCR-ABL表达的细胞。对于在靶蛋白表达点突变的耐药细胞,LCL161也具有抵抗活性。1000 nM的LCL161能够大部分或完全杀死耐PKC412的Ba/F3衍生的细胞系,其在FLT3的ATP结合囊表达含有点突变的FLT3-ITD。100到1000 nM浓度的LCL161也表现出抗Ba/F3细胞的活性, Ba/F3细胞能够表达各种伊马替尼和尼罗替尼耐药的BCR-ABL点突变。[1] 对LCL161抗23细胞系的评估,通过儿科临床前测试计划(PPTP)在体外进行96小时。对23种测试PPTP细胞系中的其中3种,10 μM浓度下的LCL161能够抑制50%的生长。3种细胞系包括2种T细胞ALL细胞系(COG-LL-317和CCRF-CEM),以及间变性大细胞淋巴瘤细胞系(Karpas-299),CCRF-CEM和Karpas-299表现出较低的相对IC50值(分别为0.25和1.6 μM)。[2] LCL161对人体免疫亚群表现出免疫调节性能。用LCL161处理T淋巴细胞显著增强具有激活作用的细胞因子分泌,对 CD4和CD8 T细胞生存或分化的作用很小。LCL161处理外周血单核细胞,在体外合成多肽存在下,显著增强初始T细胞的启动。髓样树突状细胞在LCL161作用下表型成熟,表明降低了基于肿瘤抗原对抗疫苗的能力。这些作用可能通过观察到的典型和非典型NF-κB途径的激活介导,伴随LCL161导致抗凋亡分子上调。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LOX MXfGeY5kfGmxbjDhd5NigQ>? M3f3UVExOCCvZz;r[y=> NFfNNWs5KGi{cx?= MmfvVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ2lCWDFiZHXndoFl[XSrb36gbY4hcHWvYX6gUG9ZKGOnbHzzJJhmdm:pcnHmeIVlKGmwIH3veZNmKGG2IEGwNEBu\y:tZzygdI8h[W[2ZYKgPEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?= NH3oVI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
LOX MmDLSpVv[3Srb36gZZN{[Xl? NGDDT2k5KGi{cx?= NXjZU5hXWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[2G|cHHz[UA{NzdiYXP0bZZifGmxbjDpckBpfW2jbjDMU3gh[2WubIOgfIVvd2e{YX\0[YQhcW5ibX;1d4Uh[W[2ZYKgPEBpenNiYomg[ox2d3Knc3PlcoNmKGG|c3H5 NX2zeVVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
MDA-MB-231 NYXNXHlZTnWwY4Tpc44h[XO|YYm= M1LHSVIvPSC2bzCxNEB2VQ>? NWPCUVZGOTliaILz NXXnZYlpSmmwZHnu[{Bi\m[rbnn0fUB1dyClSVHQNUBDUVJ|IHTvcYFqdiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJHRPTmGucHjhJIxmfmWuIHH0JFIvPSC2bzCxNEB2VSCjZoTldkAyQSCqcoOgZpkhTUyLU1G= M1HRe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
BxPC3 MXrGeY5kfGmxbjDhd5NigQ>? NVXNUFVYOy5|IIXN MUO1JIRigXN? NUnSNIdGWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSniSQ{OgZ4VtdHNiYYSgN{4{KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? Mnv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEO3PFIoRjJ2MEizO|gzRC:jPh?=
HCT15 NFjUOIRHfW6ldHnvckBie3OjeR?= NE\0Z5U{NjNidV2= MmjpOUBl[Xm| NIj5UmZRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzNTDj[YxteyCjdDCzMlMhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? M4\5WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
SW620 MYLGeY5kfGmxbjDhd5NigQ>? M2TFc|EvOSC3TR?= NYLNSVVsPSCmYYnz NIGzUWtRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXzZ{MDDj[YxteyCjdDCxMlEhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? NIjj[lM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
SW620 NXvIPIk6TnWwY4Tpc44h[XO|YYm= M3i4ZVMvOyC3TR?= NFrnUlA2KGSjeYO= M4LwUXBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNYPjJyIHPlcIx{KGG2IEOuN{B2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 NUHsbZBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
LOX M4XIfGZ2dmO2aX;uJIF{e2G7 M2XLbVMvOyC3TR?= M{\vVVMh\GG7cx?= NHr3NFRRd3SnboTpZZRqd25ib3[gZ49v[XS3bYXtZYIucW6mdXPl[EBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNV1hiY3XscJMh[XRiMz6zJJVOKGGodHXyJFMh\GG7czDifUBOXFNiYYPzZZk> Mn7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOEO3PFIoRjJ2MEizO|gzRC:jPh?=
LS180 M3racGZ2dmO2aX;uJIF{e2G7 MkW1N{4{KHWP NYrGcop{PSCmYYnz MVjQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMV|E5OCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
H460 Ml;PSpVv[3Srb36gZZN{[Xl? NX7XS5J3Oy5|IIXN Ml72OUBl[Xm| MoWyVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> NXzTb3dXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
LOX Ml:3SpVv[3Srb36gZZN{[Xl? MmfLNVAxKG2pL3vn Mo[xPEBpenN? NHm3NHZRdGG|bXGgZ49v[2WwdILheIlwdiCrbjDueYRmKG2xdYPlJJhmdm:pcnHmeIVlKHerdHigbJVu[W5iTF;YJINmdGy|IHH0JFExOCCvZz;r[{wheG9ibXXhd5Vz\WRiYYSgPEBpenNuIFPwJF0hOy5|IN88UU4> NIjt[mQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
SW620 NELiV4RHfW6ldHnvckBie3OjeR?= NWTxXJo5PSCmYYnz NXK0[Wo3UW6mdXP0bY9vKG:oIIPlcpNqfGm8YYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdHNidH:gZ49v[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfUwhTUN7MDC9JFYvPjZizszNMi=> M17CVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
LOX M1m4U2Z2dmO2aX;uJIF{e2G7 NYLZZm5lOTByIH3nM4to M4e0NlghcHK| M2f5[mRzfWdidYD0ZYtmKGmwIIT1cY9zKG:oIH71[IUhdW:3c3WgfIVvd2e{YX\0[YQhf2m2aDDoeY1idiCOT2igZ4VtdHNiYYSgNVAxKG2pL3vnMEBxdyCvZXHzeZJm\CCjdDC4JIhzeyxiRIL1[{B2eHSja3WgQUAyQC52IN88UU4> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
SW620 M4D0VmZ2dmO2aX;uJIF{e2G7 M1v4e|IvPSC3TR?= MkTWOUBl[Xm| NXnrdFNjUW6mdXP0bY9vKG:oIIPlcpNqfGm8YYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdHNidH:gZ49v[XS3bYXtZYIucW6mdXPl[EBieG:ydH;zbZMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[XRiMj61JJVOKGGodHXyJFUh\GG7czDifUBOXFNiYYPzZZk> NWnTcGVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
LOX M1PQZWZ2dmO2aX;uJIF{e2G7 NFvxT3EyODBibXevb4c> MU[4JIhzew>? NWrKO2p7UW5idnn2c{BqdmirYnn0bY9vKG:oIGjJRXAhSkmUMjDkc41icW5iaX6gbJVu[W5iTF;YJINmdGy|IIjlco9oemGodHXkJIlvKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ4F{eGG|ZTCzM|ch[WO2aY\peJkh[XRiMUCwJI1oN2upLDDwc{Bi\nSncjC4JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NHzLZ2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
LOX MVTGeY5kfGmxbjDhd5NigQ>? NXzIUm0zOTByIH3nM4to Mn\oPEBpenN? MYnJckB3cX[xIHnubIljcXSrb36gc4YhYEmDUDDCTXIzKGSxbXHpckBqdiCqdX3hckBNV1hiY3XscJMhgGWwb3fyZYZ1\WRiaX6gcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZZNx[XOnIEOvO{Bi[3Srdnn0fUBifCBzMECgcYcwc2duIIDvJIFnfGW{IEigbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> NGfQcXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
MDA-MB-231 NGXNUppHfW6ldHnvckBie3OjeR?= MX2wMlM4KHSxIEOuN{B2VQ>? NV3qXHNyOTliaILz NFz6PIlKdmirYnn0bY9vKG:oIHPJRXAyNzJiaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhXE6IYXzwbIEhdGW4ZXygZZQhOC5|NzD0c{A{NjNidV2gZYZ1\XJiMUmgbJJ{KGK7IFXMTXNC M4LUNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
CHL1 NVHa[oYxTnWwY4Tpc44h[XO|YYm= NF;H[JAxNjRidH:gNVAhfU1? MYqyPEBpenN? NH7VOZhKdmirYnn0bY9vKG:oIHPJRXAyKGmwIHj1cYFvKEOKTEGgZ4VtdHNiYYSgNE41KHSxIEGwJJVOKGGodHXyJFI5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NF7OSFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
SKMES1 MYHGeY5kfGmxbjDhd5NigQ>? M331XFIvPSC3TR?= NFnPWXA2KGSjeYO= M1v2ZXBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCqdX3hckBUU02HU{GgZ4VtdHNiYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? M2PhZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
Capan1 NXvXb3dnTnWwY4Tpc44h[XO|YYm= Mn3uNk42KHWP NYPTZWRFPSCmYYnz NXjrOnlLWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[XCxcITvd4l{KGmwIHj1cYFvKEOjcHHuNUBk\WyuczDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
AGS MV;GeY5kfGmxbjDhd5NigQ>? MUKyMlUhfU1? M1vaUFUh\GG7cx?= Mkj5TY5lfWO2aX;uJI9nKHOnboPpeIl7[XSrb36gc4YhcHWvYX6gRWdUKGOnbHzzJJRwKGOxbnH0eY12dWGkLXnu[JVk\WRiYYDvdJRwe2m|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHH0JFIvPSC3TTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7 M{W5NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
U118MG NIjQcGdHfW6ldHnvckBie3OjeR?= M1fxT|IvPSC3TR?= NFPGTXg2KGSjeYO= MlLoVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIlvKGi3bXHuJHUyOTiPRzDj[YxteyCjdDCyMlUhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
PC3 MXLGeY5kfGmxbjDhd5NigQ>? NYfxZphiOi53IIXN MYq1JIRigXN? MYTJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgeI8h[2:wYYT1cZVu[WJvaX7keYNm\CCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? MmO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
CCRF-CEM MmeyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tR2VOKGOnbHzzMEBIUTVyIE2gNE4zPSEQvF2u NX\hSZBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|U2OjZpPkK4OFM2PTJ4PD;hQi=>
MDA-MB-231 M2P4S2Z2dmO2aX;uJIF{e2G7 MWiyJIhzew>? MoLUTY5lfWO2aX;uJI9nKGOLQWCxJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgNkBpenNuIFXDOVAhRSByLkCwNFQh|ryPLh?= MmDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUKzNVcoRjJ6NEmyN|E4RC:jPh?=
MDA-MB-231 MkTwR5l1d3SxeHnjbZR6KGG|c3H5 NYXoNoNSPzJiaILz NXPReWpxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDFR|UxKD1iMD6wNFc5KM7:TT6= M1LG[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEmyN|E4Lz5{OES5NlMyPzxxYU6=
HEK293 MXLGeY5kfGmxbjDhd5NigQ>? NEi5[FIzKGi{cx?= MV\Jcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIF\MRWcufGGpZ3XkJHhKSVBiKIXub45wf25ib4Lp[4lvMSCrboTldoFkfGmxbjD3bZRpKG[3bHygcIVv\3SqIIXueIFo\2WmIHPhd5Bie2VvOTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJiaILzJIJ6KGmvbYXuc5Bz\WOrcHn0ZZRqd25iYYPzZZktKEWFNUCgQUAxNjB|NTFOwG0v NUftdmg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PVI{OTdpPkK4OFkzOzF5PD;hQi=>
MDA-MB-231 M{XTVmFvfGm2dX3vdkBie3OjeR?= NYnJRW55OzBibXevb4c> M3zpUVI1KGSjeYO= NF\0cHVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIjlco9oemGodHXkJIlvKEKjbHKvZ{BUS0mGIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKGe{b4f0bEBqdmirYnn0bY9vKGG2IEOwJI1oN2upIHHkcYlvcXO2ZYLl[EB3cWFib4LhcEBo[X[jZ3Wg[o9zKDJ2IHThfZM> MlPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUKzNVcoRjJ6NEmyN|E4RC:jPh?=
MDA-MB-231 Ml\USpVv[3Srb36gZZN{[Xl? M4jO[lIhcHK| MlnCTY5lfWO2aX;uJI9nKGmwdILhZ4VtdHWuYYKgZ2lCWDFiZHXndoFl[XSrb36gbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB{IHjyd{whUUN3MDC9JFAvODByNDFOwG0v NIDrOGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5NVYxOCd-M{CwPVE3ODB:L3G+
MDA-MB-231 M1;3bmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NVXiWFdlPzJiaILz NX;K[Id1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIh[my3ZTDhd5NigSxiSVO1NEA:KDBwMEC3PEDPxE1w MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7MU[wNEc,OzByOUG2NFA9N2F-
HEK293 M4nkWWZ2dmO2aX;uJIF{e2G7 M{nGcFIhcHK| NGTU[|RKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGZNSUdvdHHn[4VlKFiLQWCgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB4cXSqIH\1cIwhdGWwZ4ToJJVvfGGpZ3XkJINie3Cjc3WtPUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHntcZVvd3C{ZXPpdIl1[XSrb36gZZN{[XluIFnDOVAhRSByLkCzOUDPxE1w NGLKPGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC5NVYxOCd-M{CwPVE3ODB:L3G+
SKOV3 MUfBdI9xfG:|aYOgZZN{[Xl? NUDTUY5iPDhiaILz NFXIPZpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIGPLU3Y{KGOnbHzzJIF{e2W|c3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGodHXyJFQ5KGi{czDifUBKdmO3Q4n0[UBUOyCuaY\lMYNmdGxiYX7hcJl{cXNuIFXDOVAhRSByLkCwNUDPxE1w M1P2O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
SKOV3 MX7BdI9xfG:|aYOgZZN{[Xl? MkXENlQhcHK| MlnYTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDjZZNx[XOnLUOgZYN1cX[jdHnvckBi\nSncjCyOEBpenNiYomgTY5kfUO7dHWgV|MhdGm4ZT3j[YxtKGGwYXz5d4l{NCCHQ{WwJF0hOC5yMEOg{txONg>? M4nkc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
BL21(DE3) MVvGeY5kfGmxbjDhd5NigQ>? NXLQbYR3OiCqcoO= NHHQO4hFcXOybHHj[Y1mdnRib3[gZolwfGmweXzheIVlKEGYUF[g[pJwdSCQLYTldo1qdmGuIFjpd{B1[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gXGlCWC2ESWKzJIRwdWGrbjCoNlU{KHSxIEO0O{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KGmwY4XiZZRm\CCob4KgNkBpenNiYomgSGVNTkmDLDDJR|UxKD1iMD6wOFgh|ryPLh?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB7NUO4Okc,OzFyOUWzPFY9N2F-
BL21(DE3) M4LkOWZ2dmO2aX;uJIF{e2G7 MX[4JIhzew>? NUDvcnN[TGm|cHzhZ4Vu\W62IH;mJIJqd3SrbonsZZRm\CCDVmDGJIZzd21iTj30[ZJucW6jbDDIbZMhfGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJHhKSVBvQlnSN{Bld22jaX6gLFI2OyC2bzCzOFchemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEpTEV|KTDj[YxteyCrbnP1ZoF1\WRiZn;yJFghcHK|IHL5JGRGVE[LQTygTWM2OCB;IECuNFU{KM7:TT6= M1PlelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
A549 NHT2bHpHfW6ldHnvckBie3OjeR?= M4OyW|EhfU1? MljmN{BpenN? NFTCPJdKdmS3Y4Tpc44hd2ZiY1nBVFIh\GWpcnHkZZRqd25iaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY1nBVFIheHKxdHXpckBt\X[nbDDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV3MEG1OUc,OzF3NUCxOVU9N2F-
SK-MEL-28 NWru[m5XTnWwY4Tpc44h[XO|YYm= MnnINUB2VQ>? MUOzJIhzew>? NETHdHBKdmS3Y4Tpc44hd2ZiY1nBVFEh\GWpcnHkZZRqd25iaX6gbJVu[W5iU1utUWVNNTJ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBkUUGSMTDwdo91\WmwIHzleoVtKGG2IEGgeW0hcW6ldXLheIVlKG[xcjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NV7rdo5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G1OVAyPTVpPkOxOVUxOTV3PD;hQi=>
SK-MEL-28 MX\GeY5kfGmxbjDhd5NigQ>? NH[2SI8yKHWP NUDkUXhJOyCqcoO= MUTJcoR2[3Srb36gc4Yh[0mDUEKg[IVoemGmYYTpc44hcW5iaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDjTWFROiCycn;0[YlvKGyndnXsJIF1KDFidV2gbY5kfWKjdHXkJIZweiB|IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MoHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3NUCxOVUoRjNzNUWwNVU2RC:jPh?=
HEK293T MVPGeY5kfGmxbjDhd5NigQ>? MXixNEB2VQ>? NH64dYs3KGi{cx?= M1S4ZmNwfmGuZX70JIJqdmSrbnegZYZncW6rdImgeI8hUEFvQlnSN{Bld22jaX6gc4YhYEmDUDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJTUt{OUPUJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGKjbnSgbY51\W6|aYT5JIF1KDFyIIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz M4qzS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUWwNVU2Lz5|MUW1NFE2PTxxYU6=
A549 M2D3VmZ2dmO2aX;uJIF{e2G7 NH\U[mQyKHWP MV6zJIhzew>? Mk\OTY5lfWO2aX;uJI9nKGOLQWCxJIRm\3KjZHH0bY9vKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOLQWCxJJBzd3SnaX6gcIV3\WxiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFMhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3NUCxOVUoRjNzNUWwNVU2RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / surivivin ; 

PubMed: 27737687     


A549 and H460 cells were treated for 48 h with 0-20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting. β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
Growth inhibition assay
Cell viability; 

PubMed: 27737687     


Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
体内研究 LCL161显著增强PKC412抑制Ba/F3-FLT3-ITD-luc+细胞体内生长的能力。LCL161能够与标准化疗剂,阿糖胞苷和阿霉素阳性结合,抗FLT3-ITD表达细胞和D835Y表达细胞。Nilotinib与LCL161结合能够实现抑制白血病生长的累加作用。LCL161 (100 毫克/千克)增强高适度剂量nilotinib (100毫克/千克)对患有白血病小鼠的体内作用。[1] 通过儿科临床前测试程序(PPTP)测试CL161(口服给药,一周两次)在体内(30 或 75 毫克/千克[实体瘤] 或100 毫克/千克 [ALL])的作用。LCL161诱导显著的EFS在大约三分之一实体瘤异种移植物(osteosarcoma and glioblastoma) 中的分布差异,但不影响ALL异种移植物中的情况。没有观察到可评价客观疗效者。在体内,LCL161对儿科临床前模型研究表现出有限的单剂量活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: 人 T 细胞 ALL 细胞系 COG-LL-317
  • Concentrations: ~10 μM
  • Incubation Time: 96小时
  • Method:

    使用DIMSCAN进行体外测试


    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (199.74 mM)
Water Insoluble
Ethanol '20 mg/mL warmed

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 500.63
化学式

C26H33FN4O3S

CAS号 1005342-46-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03111992 Completed Drug: PDR001|Drug: CJM112|Drug: LCL161 Multiple Myeloma Novartis Pharmaceuticals|Novartis December 18 2017 Phase 1
NCT01934634 Unknown status Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel Metastatic Pancreatic Cancer US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC March 2014 Phase 1
NCT01968915 Completed Drug: LCL161|Drug: Paclitaxel Neoplasms Novartis Pharmaceuticals|Novartis November 2013 Phase 1
NCT01617668 Completed Drug: LCL161|Drug: paclitaxel Breast Cancer Novartis Pharmaceuticals|Novartis August 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

IAP Signaling Pathway Map

Tags: 购买LCL161 | LCL161供应商 | 采购LCL161 | LCL161价格 | LCL161生产 | 订购LCL161 | LCL161代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID